Q: What is FMT and what is it approved for?

Faecal microbiota transplantation (FMT) transfers processed gut microbiota from a healthy donor to a recipient to restore a disrupted microbiome. It received FDA approval in 2022-2023 specifically and exclusively for recurrent Clostridioides difficile infection (C. diff) — a life-threatening recurrent gut infection that destroys normal gut flora and creates conditions for C. diff overgrowth. The cure rates are remarkable: FMT achieves approximately 90% success for recurrent C. diff vs approximately 30% for additional antibiotic courses. FDA-approved products: Rebyota (enema form, Ferring) and Vowst (oral capsules, Seres). FMT is being investigated for other conditions (IBD, obesity, autism, metabolic syndrome) in clinical trials — but is NOT approved for these uses.

Q: What is the gut-brain axis?

The gut-brain axis is the bidirectional communication network connecting the gut microbiome and the central nervous system. Key pathways: Vagus nerve (the primary highway — carries electrochemical signals from 100 million neurons in the enteric nervous system directly to the brainstem). Microbial metabolites (SCFAs cross into circulation and can reach the brain; tryptophan is a serotonin precursor produced partly by gut bacteria; GABA precursors are made by Lactobacillus species). Immune signals (cytokines from gut-associated immune tissue can cross the blood-brain barrier). The gut produces approximately 90% of the body's serotonin — though this peripheral serotonin does not cross the blood-brain barrier. Clinical evidence: germ-free mice have profoundly altered behaviour (more anxious, socially impaired); these deficits are partially corrected by FMT from normal mice — establishing causality in animals. Human clinical evidence is mainly observational — microbiome differences associated with depression, anxiety, autism — but causality not yet established.

Q: What actually helps the microbiome?

Evidence-based interventions: (1) Dietary fibre: the single most evidence-based microbiome intervention — feeds beneficial bacteria, increases SCFA production, maintains microbiome diversity. WHO recommends ≥25g/day; sources: vegetables, legumes, whole grains, fruit, nuts. (2) Fermented foods: yogurt, kefir, kimchi, sauerkraut — a landmark 2021 Cell study (Wastyk et al.) showed high-fermented-food diet increased microbiome diversity and reduced inflammatory markers over 10 weeks. (3) Mediterranean diet: consistently associated with higher microbiome diversity. (4) Avoiding unnecessary antibiotics: antibiotics cause profound, persistent microbiome disruption. (5) FMT: for recurrent C. diff (FDA-approved). (6) Specific probiotic strains for specific conditions (see above). What does not clearly help: commercial probiotic supplements for general wellness; commercial prebiotic supplements beyond a high-fibre diet.

Q: How does GMJ News cover the microbiome?

GMJ News covers the 100 trillion organism ecosystem, gut-brain axis science, FMT FDA approval (Rebyota, Vowst), the 90% C. diff cure rate, specific probiotic evidence (C. diff prevention, NEC, rotavirus), SCFA physiology and fibre evidence, dysbiosis and its limitations, Akkermansia muciniphila as emerging research, and the direct-to-consumer microbiome testing evidence gap. GMJ position: the microbiome is a genuine and fascinating area of science with FMT as a proven clinical breakthrough; most probiotic and microbiome supplement marketing vastly outstrips the evidence; dietary fibre remains the most evidence-based microbiome intervention.

Question 1

What is the microbiome and why does it matter?

Accepted Answer

The human gut microbiome is the community of approximately 100 trillion microorganisms — predominantly bacteria, but also archaea, viruses and fungi — living in the gastrointestinal tract. This community evolved with humans over millions of years and is essential for: digestion of dietary fibre (producing short-chain fatty acids — SCFAs); education and regulation of the immune system (70% of immune tissue is gut-associated); production of vitamins (K, B12, folate); protection against pathogenic bacteria (colonisation resistance); communication with the brain (gut-brain axis). The microbiome is as individual as a fingerprint — shaped by birth (vaginal vs caesarean), infant feeding (breast milk vs formula), antibiotic exposure, diet and geography.

Question 2

What is FMT and what is it approved for?

Accepted Answer

Faecal microbiota transplantation (FMT)
FDA/NEJMTransfer of processed donor faecal material (containing gut microbiota) into a recipient's gastrointestinal tract to restore a healthy microbial community. Methods: colonoscopic infusion (most established); nasal-jejunal tube; enema (Rebyota, RBX2660); oral capsules (Vowst, SER-109 — spore-based, heat-treated). Donor screening (strict): HIV, HBV, HCV, CMV, EBV, parasites, C. diff, multidrug-resistant organisms. FDA-approved only for recurrent C. diff. Under clinical trial for: IBD (ulcerative colitis — promising Phase 2 results); metabolic syndrome; autism (pilot studies); ME/CFS; multiple sclerosis.

Question 3

Do probiotics work?

Accepted Answer

It depends on which probiotic, for which condition, in which patient — "probiotics" is not a homogeneous category. The evidence clearly supports specific probiotics for specific conditions: C. diff prevention during antibiotic therapy: Cochrane 2017 shows approximately 60% risk reduction with Lactobacillus rhamnosus GG or Saccharomyces boulardii in hospitalised patients on antibiotics. Infant necrotising enterocolitis (NEC) prevention: probiotics reduce NEC risk in premature infants (NICE recommends for premature neonates <32 weeks). Rotavirus diarrhoea: modest reduction in duration. IBS: some strains reduce bloating and pain in IBS (inconsistent across strains). The evidence does NOT support probiotics for: depression; autism; immune enhancement in healthy adults; weight loss; most other marketed claims. Most commercial probiotic products are not the strains used in clinical trials.

Question 4

What is the gut-brain axis?

Accepted Answer

The gut-brain axis is the bidirectional communication network connecting the gut microbiome and the central nervous system. Key pathways: Vagus nerve (the primary highway — carries electrochemical signals from 100 million neurons in the enteric nervous system directly to the brainstem). Microbial metabolites (SCFAs cross into circulation and can reach the brain; tryptophan is a serotonin precursor produced partly by gut bacteria; GABA precursors are made by Lactobacillus species). Immune signals (cytokines from gut-associated immune tissue can cross the blood-brain barrier). The gut produces approximately 90% of the body's serotonin — though this peripheral serotonin does not cross the blood-brain barrier. Clinical evidence: germ-free mice have profoundly altered behaviour (more anxious, socially impaired); these deficits are partially corrected by FMT from normal mice — establishing causality in animals. Human clinical evidence is mainly observational — microbiome differences associated with depression, anxiety, autism — but causality not yet established.

Question 5

What actually helps the microbiome?

Accepted Answer

Evidence-based interventions: (1) Dietary fibre: the single most evidence-based microbiome intervention — feeds beneficial bacteria, increases SCFA production, maintains microbiome diversity. WHO recommends ≥25g/day; sources: vegetables, legumes, whole grains, fruit, nuts. (2) Fermented foods: yogurt, kefir, kimchi, sauerkraut — a landmark 2021 Cell study (Wastyk et al.) showed high-fermented-food diet increased microbiome diversity and reduced inflammatory markers over 10 weeks. (3) Mediterranean diet: consistently associated with higher microbiome diversity. (4) Avoiding unnecessary antibiotics: antibiotics cause profound, persistent microbiome disruption. (5) FMT: for recurrent C. diff (FDA-approved). (6) Specific probiotic strains for specific conditions (see above). What does not clearly help: commercial probiotic supplements for general wellness; commercial prebiotic supplements beyond a high-fibre diet.

Question 6

How does GMJ News cover the microbiome?

Accepted Answer

GMJ News covers the 100 trillion organism ecosystem, gut-brain axis science, FMT FDA approval (Rebyota, Vowst), the 90% C. diff cure rate, specific probiotic evidence (C. diff prevention, NEC, rotavirus), SCFA physiology and fibre evidence, dysbiosis and its limitations, Akkermansia muciniphila as emerging research, and the direct-to-consumer microbiome testing evidence gap. GMJ position: the microbiome is a genuine and fascinating area of science with FMT as a proven clinical breakthrough; most probiotic and microbiome supplement marketing vastly outstrips the evidence; dietary fibre remains the most evidence-based microbiome intervention.

GMJ News

Microbiome & Gut Health

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company